RNS Number : 7784Q
OptiBiotix Health PLC
02 March 2021

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Director Appointment

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 2 February 2021 regarding the intention to appoint Stephen Hammond MP as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Stephen will join the Board as a Non-Executive Director with immediate effect. The text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Stephen William Hammond (aged 59):

Current Appointments	**Appointments in the last five years**
Harwood Film Partnership LLP	Commonwealth Parliamentary Association (United Kingdom Branch)
Peal Gas LLC	G-Volution Limited
	South Coast Regeneration & Investment Property Co Limited

In December 2020 The Office of the Advisory Committee on Business Appointments noted that whilst Stephen Hammond had complied with the House of Commons regulatory disclosure requirements, he did not seek advice as he was required to do in relation to his role at Public Policy Projects, a think tank policy institute, and as a consequence had breached Government's Rules and the requirement set out in the Ministerial Code.

Stephen Hammond MP does not currently own any shares or options in the Company.

There is no further information regarding Stephen Hammond MP required to be disclosed under the AIM Rules.

Neil Davidson, Chairman of OptiBiotix commented: "*We are pleased to confirm the appointment of Stephen Hammond which reflects the continued development of the*

Company and the ambition of the Board to build a profitable international business with global brands.

"The Company anticipate that there will be further additions and changes to the Board and management teams as it continues to grow sales, expand into international markets and commercialises its next generation products."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the content of this announcement.

For further information, please contact:

OptiBiotix Health plc — www.optibiotix.com
Neil Davidson, Chairman — *Contact via Walbrook below*
Stephen O'Hara, Chief Executive

Cairn Financial Advisers LLP (NOMAD) — Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti

finnCap (Broker) — Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)

Walbrook PR Ltd — Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact

rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUPUQWWUPGPUG